Leerink Partners Assumes Contineum Therapeutics (CTNM) at Outperform
Tweet
Share
E-mailGet Alerts CTNM Hot Sheet
Price: $14.19 -7.25%
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Partners analyst Roanna Ruiz assumes coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Contineum Therapeutics click here. For more ratings news on Contineum Therapeutics click here.
Shares of Contineum Therapeutics closed at $11.47 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- Leerink Starts Freenome Inc. (FRNM) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
